<DOC>
	<DOC>NCT00904540</DOC>
	<brief_summary>Patients with acute or chronic Lower Back Pain (LBP) participated in a Phase IV clinical trial to assess the effectiveness of Lidoderm administered once daily (q24h) for 2 weeks in the treatment of acute and chronic LBP.</brief_summary>
	<brief_title>Topical Lidocaine Patch in Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Nonradicular LBP pain for â‰¤12 months (nonradicular defined as LBP that does not radiate below the midbuttock and with no sensory symptoms in the leg) Had LBP as the primary source of pain. Patients may have had mild to moderate spinal stenosis and no radicular symptoms Had an average daily pain intensity score of &gt;4 on a 0 to 10 scale, with 0 being no pain and 10 being pain as bad as the patients have ever imagined (Question 5 of BPI) within 24 hours prior to the screening visit. Had a normal neurological examination, including: Motor strength Sensory testing (light touch, pinprick, and vibration) Deep tendon reflexes Patients were eligible for participation in the longterm chronic (&gt;12 months) group of the study if they also: Had LBP for greater than one year. Patients may have had any of the following: lumbar degenerative disc disease, internal disc disruption, mildtosevere spinal stenosis, degenerative scoliosis and spondylolisthesis, facet arthropathy Had a history of greater than one back surgery or one back surgery within 3 months of study entry Had severe spinal stenosis and radicular symptoms Had any other chronic pain condition that, in the opinion of the investigator, would have interfered with patient assessment of LBP relief Had received an epidural steroid/local anesthetic injection within 2 weeks prior to study entry Had received trigger point injections within 2 weeks prior to study entry Had received Botox Injections within 3 months prior to study entry Were taking a lidocainecontaining product that could not be discontinued while receiving Lidoderm Were taking class 1 antiarrhythmic drugs (e.g., mexiletine, tocainide) Patients were excluded from participation in the longterm chronic (&gt;12 months) group if they also: Had an undefined spinal diagnosis Had a history of lumbar spine surgery within 6 months prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>